Search

Search Bar
01/12/2023 Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(6)DOI:10.1016/j.jaad.2023.07.1024. PMID:37553030. IF:12.800(Q1/1D).
01/12/2023 Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.
Egeberg A, Kristensen LE, Puig L, Rich P, Smith SD, Garrelts A, See K, Holzkaemper T, Fotiou K, Schuster C. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.. JOURNAL OF DERMATOLOGICAL TREATMENT. 2023; 34(1)DOI:10.1080/09546634.2023.2263108. PMID:37781881. IF:2.900(Q2/4D).
01/11/2023 [[Translated Article]]Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology.
Puig L. [[Translated Article]]Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology.. Actas Dermo-Sifiliograficas. 2023; 114(10)DOI:10.1016/j.ad.2023.09.020. PMID:37778620. IF:(Q/D).
01/10/2023 Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review.
Girolomoni G, Savage L, Gisondi P, Svensson Å, Mahé E, Augustin M, Puig L. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review.. Dermatology and Therapy. 2023; 13(10)DOI:10.1007/s13555-023-01014-x. PMID:37710078. IF:3.500(Q1/3D).